Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

Ipsen's Somatuline Gets Marketing Approval In Japan - Quick Facts

Ipsen (IPSEF.PK) said its partner Teijin obtained manufacturing and marketing approval from the Japan's Ministry of Health, Labour and Welfare for Somatuline 60/90/120 mg for s.c. injection (lanreotide acetate). In Japan, Somatuline is indicated for the treatment of growth hormone and IGF-I (somatomedin-C) hypersecretion and related symptoms in acromegaly and pituitary gigantism.

The company noted that Somatuline will be available in a new enhanced presentation with a pre-filled syringe that does not need reconstitution and with a retractable needle that improves safety for caregivers.

Click here to receive FREE breaking news email alerts for Ipsen Promesses and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Stocks moved notably higher over the course of the trading day on Monday, extending the strong upward move seen last Friday. The gains on the day continued the recent recovery by the markets, with the Nasdaq and the S&P 500 closing higher for the third consecutive session. While Republicans have largely tried to frame the upcoming midterm elections as a referendum on President Barack Obama, Sen. Ted Cruz, R-Tex., has joined the few offering guidance on what the GOP will do if it manages to retake control of the Senate. The World Health Organization (WHO) Monday declared that Nigeria is officially free of Ebola virus transmission. For the last six weeks, no new cases of the deadly virus infection has been reported in the country. The lines on the tabular situation reports, sent to WHO each day by its country office in Nigeria, have now been full of zeros for 42 days. If two incubation periods of 21 days pass
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.